Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Chugai Pharmaceutical Co ( (JP:4519) ).
Chugai Pharmaceutical has completed the process of making Renalys Pharma, Inc. a wholly owned subsidiary and has finalized an absorption-type merger, with Chugai as the surviving entity and Renalys Pharma as the dissolved company. The move consolidates Renalys Pharma’s operations and assets under Chugai’s corporate structure, streamlining its organization and potentially enhancing operational efficiency and integration of its pharmaceutical development activities.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9169.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, focusing on the research, development, manufacturing and marketing of prescription drugs. Headquartered in Tokyo, the company operates globally with a portfolio centered on innovative therapies and partnerships that strengthen its position in the pharmaceutical and biotechnology markets.
Average Trading Volume: 2,653,555
Technical Sentiment Signal: Buy
Current Market Cap: Yen13828.2B
Find detailed analytics on 4519 stock on TipRanks’ Stock Analysis page.